Although improvements have been made in the fields of NSCLC treatment, especially for adenocarcinomas with actionable mutations such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), certain Kirsten rat sarcoma virus (K-RAS) variants, and more recently with checkpoint inhibitors [3], resistance often sets in [4,5,6]; and the overall 5-year survival rate remains low (<30%) [7]. This evidence concerns the gene ALK and non-small cell lung carcinoma.